333 related articles for article (PubMed ID: 35658487)
21. Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050/GOG 3015/ENGOT-OV39).
Moore KN; Bookman M; Sehouli J; Miller A; Anderson C; Scambia G; Myers T; Taskiran C; Robison K; Mäenpää J; Willmott L; Colombo N; Thomes-Pepin J; Liontos M; Gold MA; Garcia Y; Sharma SK; Darus CJ; Aghajanian C; Okamoto A; Wu X; Safin R; Wu F; Molinero L; Maiya V; Khor VK; Lin YG; Pignata S
J Clin Oncol; 2021 Jun; 39(17):1842-1855. PubMed ID: 33891472
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and safety of rucaparib in previously treated, locally advanced or metastatic urothelial carcinoma from a phase 2, open-label trial (ATLAS).
Grivas P; Loriot Y; Morales-Barrera R; Teo MY; Zakharia Y; Feyerabend S; Vogelzang NJ; Grande E; Adra N; Alva A; Necchi A; Rodriguez-Vida A; Gupta S; Josephs DH; Srinivas S; Wride K; Thomas D; Simmons A; Loehr A; Dusek RL; Nepert D; Chowdhury S
BMC Cancer; 2021 May; 21(1):593. PubMed ID: 34030643
[TBL] [Abstract][Full Text] [Related]
23. Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial.
Moore KN; Secord AA; Geller MA; Miller DS; Cloven N; Fleming GF; Wahner Hendrickson AE; Azodi M; DiSilvestro P; Oza AM; Cristea M; Berek JS; Chan JK; Rimel BJ; Matei DE; Li Y; Sun K; Luptakova K; Matulonis UA; Monk BJ
Lancet Oncol; 2019 May; 20(5):636-648. PubMed ID: 30948273
[TBL] [Abstract][Full Text] [Related]
24. Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2.
Oza AM; Tinker AV; Oaknin A; Shapira-Frommer R; McNeish IA; Swisher EM; Ray-Coquard I; Bell-McGuinn K; Coleman RL; O'Malley DM; Leary A; Chen LM; Provencher D; Ma L; Brenton JD; Konecny GE; Castro CM; Giordano H; Maloney L; Goble S; Lin KK; Sun J; Raponi M; Rolfe L; Kristeleit RS
Gynecol Oncol; 2017 Nov; 147(2):267-275. PubMed ID: 28882436
[TBL] [Abstract][Full Text] [Related]
25. Treatment With Niraparib Maintenance Therapy in Patients With Newly Diagnosed Advanced Ovarian Cancer: A Phase 3 Randomized Clinical Trial.
Li N; Zhu J; Yin R; Wang J; Pan L; Kong B; Zheng H; Liu J; Wu X; Wang L; Huang Y; Wang K; Zou D; Zhao H; Wang C; Lu W; Lin A; Lou G; Li G; Qu P; Yang H; Zhang Y; Cai H; Pan Y; Hao M; Liu Z; Cui H; Yang Y; Yao S; Zhen X; Hang W; Hou J; Wang J; Wu L
JAMA Oncol; 2023 Sep; 9(9):1230-1237. PubMed ID: 37440217
[TBL] [Abstract][Full Text] [Related]
26. Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.
González-Martín A; Pothuri B; Vergote I; DePont Christensen R; Graybill W; Mirza MR; McCormick C; Lorusso D; Hoskins P; Freyer G; Baumann K; Jardon K; Redondo A; Moore RG; Vulsteke C; O'Cearbhaill RE; Lund B; Backes F; Barretina-Ginesta P; Haggerty AF; Rubio-Pérez MJ; Shahin MS; Mangili G; Bradley WH; Bruchim I; Sun K; Malinowska IA; Li Y; Gupta D; Monk BJ;
N Engl J Med; 2019 Dec; 381(25):2391-2402. PubMed ID: 31562799
[TBL] [Abstract][Full Text] [Related]
27. Antitumor activity of the poly(ADP-ribose) polymerase inhibitor rucaparib as monotherapy in patients with platinum-sensitive, relapsed,
Kristeleit RS; Oaknin A; Ray-Coquard I; Leary A; Balmaña J; Drew Y; Oza AM; Shapira-Frommer R; Domchek SM; Cameron T; Maloney L; Goble S; Lorusso D; Ledermann JA; McNeish IA
Int J Gynecol Cancer; 2019 Nov; 29(9):1396-1404. PubMed ID: 31685558
[TBL] [Abstract][Full Text] [Related]
28. Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial.
Ledermann JA; Harter P; Gourley C; Friedlander M; Vergote I; Rustin G; Scott C; Meier W; Shapira-Frommer R; Safra T; Matei D; Fielding A; Spencer S; Rowe P; Lowe E; Hodgson D; Sovak MA; Matulonis U
Lancet Oncol; 2016 Nov; 17(11):1579-1589. PubMed ID: 27617661
[TBL] [Abstract][Full Text] [Related]
29. Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial.
Ray-Coquard I; Leary A; Pignata S; Cropet C; González-Martín A; Marth C; Nagao S; Vergote I; Colombo N; Mäenpää J; Selle F; Sehouli J; Lorusso D; Guerra Alia EM; Bogner G; Yoshida H; Lefeuvre-Plesse C; Buderath P; Mosconi AM; Lortholary A; Burges A; Medioni J; El-Balat A; Rodrigues M; Park-Simon TW; Dubot C; Denschlag D; You B; Pujade-Lauraine E; Harter P;
Ann Oncol; 2023 Aug; 34(8):681-692. PubMed ID: 37211045
[TBL] [Abstract][Full Text] [Related]
30. PARP inhibitors as maintenance therapy in newly diagnosed advanced ovarian cancer: a meta-analysis.
Lin Q; Liu W; Xu S; Shang H; Li J; Guo Y; Tong J
BJOG; 2021 Feb; 128(3):485-493. PubMed ID: 32654312
[TBL] [Abstract][Full Text] [Related]
31. Efficacy of Maintenance Olaparib for Patients With Newly Diagnosed Advanced Ovarian Cancer With a BRCA Mutation: Subgroup Analysis Findings From the SOLO1 Trial.
DiSilvestro P; Colombo N; Scambia G; Kim BG; Oaknin A; Friedlander M; Lisyanskaya A; Floquet A; Leary A; Sonke GS; Gourley C; Banerjee S; Oza A; González-Martín A; Aghajanian CA; Bradley WH; Mathews CA; Liu J; Lowe ES; Bloomfield R; Moore KN
J Clin Oncol; 2020 Oct; 38(30):3528-3537. PubMed ID: 32749942
[TBL] [Abstract][Full Text] [Related]
32. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial.
Ledermann J; Harter P; Gourley C; Friedlander M; Vergote I; Rustin G; Scott CL; Meier W; Shapira-Frommer R; Safra T; Matei D; Fielding A; Spencer S; Dougherty B; Orr M; Hodgson D; Barrett JC; Matulonis U
Lancet Oncol; 2014 Jul; 15(8):852-61. PubMed ID: 24882434
[TBL] [Abstract][Full Text] [Related]
33. Homologous Recombination Repair Gene Mutations to Predict Olaparib Plus Bevacizumab Efficacy in the First-Line Ovarian Cancer PAOLA-1/ENGOT-ov25 Trial.
Pujade-Lauraine E; Brown J; Barnicle A; Wessen J; Lao-Sirieix P; Criscione SW; du Bois A; Lorusso D; Romero I; Petru E; Yoshida H; Vergote I; Colombo N; Hietanen S; Provansal M; Schmalfeldt B; Pignata S; Martín Lorente C; Berton D; Runnebaum IB; Ray-Coquard I
JCO Precis Oncol; 2023 Jan; 7():e2200258. PubMed ID: 36716415
[TBL] [Abstract][Full Text] [Related]
34. Efficacy of subsequent chemotherapy for patients with BRCA1/2-mutated recurrent epithelial ovarian cancer progressing on olaparib versus placebo maintenance: post-hoc analyses of the SOLO2/ENGOT Ov-21 trial.
Frenel JS; Kim JW; Aryal N; Asher R; Berton D; Vidal L; Pautier P; Ledermann JA; Penson RT; Oza AM; Korach J; Huzarski T; Pignata S; Colombo N; Park-Simon TW; Tamura K; Sonke GS; Freimund AE; Lee CK; Pujade-Lauraine E
Ann Oncol; 2022 Oct; 33(10):1021-1028. PubMed ID: 35772665
[TBL] [Abstract][Full Text] [Related]
35. A Randomized, Double-Blind, Biomarker-Selected, Phase II Clinical Trial of Maintenance Poly ADP-Ribose Polymerase Inhibition With Rucaparib Following Chemotherapy for Metastatic Urothelial Carcinoma.
Crabb SJ; Hussain S; Soulis E; Hinsley S; Dempsey L; Trevethan A; Song Y; Barber J; Frew J; Gale J; Faust G; Brock S; McGovern U; Parikh O; Enting D; Sundar S; Ratnayake G; Lees K; Birtle AJ; Powles T; Jones RJ
J Clin Oncol; 2023 Jan; 41(1):54-64. PubMed ID: 35960902
[TBL] [Abstract][Full Text] [Related]
36. Impact of veliparib, paclitaxel dosing regimen, and germline BRCA status on the primary treatment of serous ovarian cancer - an ancillary data analysis of the VELIA trial.
Aghajanian C; Swisher EM; Okamoto A; Steffensen KD; Bookman MA; Fleming GF; Friedlander M; Moore KN; Tewari KS; O'Malley DM; Chan JK; Ratajczak C; Hashiba H; Wu M; Dinh MH; Coleman RL
Gynecol Oncol; 2022 Feb; 164(2):278-287. PubMed ID: 34930617
[TBL] [Abstract][Full Text] [Related]
37. Olaparib maintenance monotherapy in platinum-sensitive relapsed ovarian cancer patients without a germline BRCA1/BRCA2 mutation: OPINION primary analysis.
Poveda A; Lheureux S; Colombo N; Cibula D; Lindemann K; Weberpals J; Bjurberg M; Oaknin A; Sikorska M; González-Martín A; Madry R; Pérez MJR; Ledermann J; Davidson R; Blakeley C; Bennett J; Barnicle A; Škof E
Gynecol Oncol; 2022 Mar; 164(3):498-504. PubMed ID: 35063276
[TBL] [Abstract][Full Text] [Related]
38. Rucaparib: A Poly(ADP-Ribose) Polymerase Inhibitor for BRCA-Mutated Relapsed Ovarian Cancer.
Moore DC; Ringley JT; Patel J
J Pharm Pract; 2019 Apr; 32(2):219-224. PubMed ID: 29166829
[TBL] [Abstract][Full Text] [Related]
39. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial.
Pujade-Lauraine E; Ledermann JA; Selle F; Gebski V; Penson RT; Oza AM; Korach J; Huzarski T; Poveda A; Pignata S; Friedlander M; Colombo N; Harter P; Fujiwara K; Ray-Coquard I; Banerjee S; Liu J; Lowe ES; Bloomfield R; Pautier P;
Lancet Oncol; 2017 Sep; 18(9):1274-1284. PubMed ID: 28754483
[TBL] [Abstract][Full Text] [Related]
40. Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.
Moore K; Colombo N; Scambia G; Kim BG; Oaknin A; Friedlander M; Lisyanskaya A; Floquet A; Leary A; Sonke GS; Gourley C; Banerjee S; Oza A; González-Martín A; Aghajanian C; Bradley W; Mathews C; Liu J; Lowe ES; Bloomfield R; DiSilvestro P
N Engl J Med; 2018 Dec; 379(26):2495-2505. PubMed ID: 30345884
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
